Glioblastoma Patients Treated With Bevacizumab Experience Reduced Cognitive Function And Quality Of
Many glioblastoma patients treated with bevacizumab (Avastin®) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center...
No comments:
Post a Comment